<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2321">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04382547</url>
  </required_header>
  <id_info>
    <org_study_id>IBCE_MSC2(Covid)</org_study_id>
    <nct_id>NCT04382547</nct_id>
  </id_info>
  <brief_title>Treatment of Covid-19 Associated Pneumonia With Allogenic Pooled Olfactory Mucosa-derived Mesenchymal Stem Cells</brief_title>
  <official_title>Treatment of Covid-19 Associated Pneumonia With Allogenic Pooled Olfactory Mucosa-derived Mesenchymal Stem Cells</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Belarusian State Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Treatment of patients with Covid-19 associated pneumonia using intravenous injection of
      allogenic pooled olfactory mucosa-derived mesenchymal stem cells
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      During the implementation of the project, it is planned to develop a method for the treatment
      of severe covid-19 associated interstitial pneumonia using allogeneic mesenchymal stem cells.
      The positive outlook for the effectiveness of MSCs is due to the following:

        -  knowledge of the leading role of immunopathogenetic mechanisms in the development of
           acute interstitial lung diseases and the pronounced immunomodulating properties of MSCs;

        -  high tropism of MSCs to lung tissue when administered intravenously;

        -  the ability of MSCs to stimulate tissue regeneration and the effective use of MSCs in
           the treatment of acute damage to the myocardium and kidneys, which will contribute to
           the treatment of multiple organ failure;

        -  positive results of preclinical studies of the method of treatment of viral pneumonia in
           animals, and the first clinical studies in patients.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">May 11, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of cured patients</measure>
    <time_frame>3 weeks</time_frame>
    <description>Number of patients cured, assessed by PCR in addition to chest CT scan</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with treatment-related adverse events</measure>
    <time_frame>3 weeks</time_frame>
    <description>MSC infusion related adverse events assessed by blood count, liver and function tests</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>COVID</condition>
  <condition>Covid-19</condition>
  <condition>Coronavirus</condition>
  <condition>Pneumonia</condition>
  <condition>Pneumonia, Viral</condition>
  <condition>Pneumonia, Interstitial</condition>
  <condition>Sars-CoV2</condition>
  <arm_group>
    <arm_group_label>mesenchymal stem cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with Covid-19 associated pneumonia receiving standard treatment and allogenic pooled olfactory mucosa-derived mesenchymal stem cells</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with Covid-19 associated pneumonia receiving standard treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Allogenic pooled olfactory mucosa-derived mesenchymal stem cells</intervention_name>
    <description>Allogenic pooled olfactory mucosa-derived mesenchymal stem cells</description>
    <arm_group_label>mesenchymal stem cells</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard treatment according to the Clinical protocols</intervention_name>
    <description>Standard treatment according to the Clinical protocols</description>
    <arm_group_label>control</arm_group_label>
    <arm_group_label>mesenchymal stem cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  PCR-confirmed Covid-19 pneumonia

          -  respiratory failure

        Exclusion Criteria:

          -  diagnosed cancer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrei Y Hancharou, Dr.</last_name>
    <role>Study Director</role>
    <affiliation>Director, the Institute of Biophysics and Cell Engineering of NAS of Belarus</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eduard A Dotsenko, Dr., prof.</last_name>
    <role>Study Director</role>
    <affiliation>Head of the chair, Belarusian State Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Natalia G Antonevich, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Head of the Lab of Institute of Biophysics and Cell Engineering of NAS</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus</name>
      <address>
        <city>Minsk</city>
        <zip>220072</zip>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belarus</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 8, 2020</study_first_submitted>
  <study_first_submitted_qc>May 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 11, 2020</study_first_posted>
  <last_update_submitted>May 26, 2020</last_update_submitted>
  <last_update_submitted_qc>May 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pneumonia</keyword>
  <keyword>Sars-COV2</keyword>
  <keyword>Covid-19</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia, Viral</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Lung Diseases, Interstitial</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

